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KEY INSIGHTS 
1. Kenya is the country that shows the most
promise as an option for business expansion in
Sub-Saharan Africa.
2. Even in the case scenario of lower than
expected demand and higher than expected
currency devaluation, vertical integration leads
to more benefits than the status quo.
3. There is value in implementing vertical
integration in stages rather than all at once to
maintain flexibility to adapt to uncertain market
conditions
 
 
 
 
 
 
Introduction 
As a global leader in the pharmaceutical industry, 
PharmaComp, the company profiled in this study, has 
the potential to realize significant value and 
competitive advantage in Africa; a continent where 
current growth projections by 2020 are comparable to 
those of China. Recent projections obtained by 
PharmaComp, show that by 2020 it is estimated that 
the population in Africa will reach 1.3 billion people. By 
then the per capita pharma spending is also expected 
to rise from the current 17.4 USD to about 40 USD. 
Spurred by a rising spending power and by the 
mounting cost of fighting diseases, Africa’s healthcare 
spending was raised from $28.4 billion in 2000 to $117 
billion in 2012 (Holt, Lahrichi, & Santos da Silva, 
2015). Future projections of the continent’s business 
potential have shifted dramatically in recent years. As 
a result, Sub-Saharan Africa (SSA) has become a 
priority for many global pharmaceutical companies 
including PharmaComp. The company is now 
examining its current supply chain strategy for SSA in 
order to position itself as a future market leader in the 
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region with a focus on increasing responsiveness to 
patients. 
Comprised of 54 countries with a population of about 
a billion people, Africa offers huge consumer market 
potential for pharmaceutical companies. However the 
challenges for developing a sustainable market 
strategy are daunting and supply chain distribution is 
one of them.  
To address these challenges, PharmaComp has 
recently launched a new strategy for Africa in an effort 
to expand its footprint on the continent. It plans to 
focus on 20 countries in a phased manner, having 
started with seven so called “Wave I1” countries in 
2015, with a particular focus on the “Wave IA” 
countries of Ghana, Nigeria, Kenya, and Côte d’Ivoire 
Yet for PharmaComp to truly realize the African 
Opportunity, it needs to fully understand the supply 
chain, including final price to patient, supply chain 
inefficiencies, barriers and opportunities for better 
distribution. It should also put in place effective 
mechanisms to ensure on-going understanding of the 
Sub-Saharan Africa distribution network. 
Problem Definition 
The objective of the thesis is to develop supply chain 
and business strategies that will enable PharmaComp 
to improve sales growth and access to more patients 
in SSA, while taking into consideration local business 
conditions, relevant risks, tradeoffs, and other options 
that could influence its decisions in the future. The 
company’s current drug distribution network is very 
fragmented and contains a large number of 
intermediaries, thereby limiting its ability to efficiently 
distribute quality products to patients in the region. 
Ultimately PharmaComp would need to take on more 
responsibility in the downstream supply chain by 
vertically integrating with a local partner in order to 
address core issues in its supply and distribution 
chain. This thesis sought to answer the question: 
How far should PharmaComp vertically integrate with 
their downstream supply chain to properly balance risk 
and benefit in Sub-Saharan Africa? 
Methodology 
To achieve this goal, we structured our analysis as 
follows: 
                                                 
1 Wave I countries: Kenya, Nigeria, Ghana, Côte d’Ivoire, 
Gabon, Angola, and Ethiopia 
First, we explored academic and popular literature to 
identify best practices that have been implemented in 
SSA by pharma and non-pharmaceutical companies.  
Second, by using a questionnaire that was distributed 
to PharmaComp internal staff and country 
representatives, we developed a benchmark to 
measure the downstream supply chain management. 
Feedback from the questionnaire suggested that 
many of the downstream problems are linked with lack 
of communication, cold chain failure, counterfeit 
drugs, and backlogs and stockouts, which could 
hopefully be improved upon with greater supply chain 
control. 
 
Third, by using information from third party reliable 
sources (such as The World Bank, The World Health 
Organization, and The Heritage Foundation), we 
developed a scorecard to help compare and rank each 
of the Wave I countries in terms of risks and candidacy 
for business expansion. The countries were ranked on 
a scale from 1 to 5. Based on qualities like political and 
economic stability, logistical infrastructure, the state of 
the healthcare industry and the efficiency of trade, the 
scorecard indicated that Kenya is the Wave I country 
best suited for business expansion for PharmaComp. 
Thus Kenya was selected as a case study country for 
the remainder of the thesis. 
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Fourth, we conducted an As-Is Analysis to determine 
the company’s current position within SSA and to 
study projections of where business will be heading 
within the next several years in the region.  
Finally, a series of scenarios consisting of different 
levels of vertical integration were selected to be 
evaluated further in the business case analysis. 
Controlling more of the supply chain would reduce 
cold chain failures, introduction of counterfeit drugs, 
and stock outs and backlogs; however, such a move 
could also require a high upfront investment in a 
market that may ultimately prove not to be profitable. 
In order to determine which level of vertical integration 
PharmaComp should consider moving forward, we 
selected three scenarios that incrementally increase 
the responsibility level. The three scenarios are 
described and depicted below:  
1. As-Is: PharmaComp will continue to operate as 
it currently does, using direct shipments from 
Europe and having product changing hands at 
the country airport. 
2. Scenario I: PharmaComp will invest in the 
creation of an affiliate company in the host 
country. With this new affiliate, PharmaComp will 
manage a warehouse of owned inventory within 
the country. They will also assume the risk that 
comes from selling their products in the local 
currency. Secondary distribution to customers 
will continue in the same way it is currently 
operating. 
3. Scenario II: PharmaComp will invest in the 
creation of an affiliate company in the host 
company and also take responsibility for the 
distribution of products to their top customers. 
They will manage a warehouse of owned 
inventory, assume the risk of selling in a foreign 
currency, and also manage part of the secondary 
distribution.  
Given the fact that the scorecard identified Kenya as 
the top candidate for SSA expansion, our Phase II 
analysis will focus on applying the above scenarios to 
the Kenyan distribution system. 
 
 
A business tool was then developed to analyze these 
three scenarios and to project the likely financial 
impact and other business consequences of their 
implementation. Due to the level of inherent 
uncertainty and risk associated with investing in Sub-
Saharan Africa, we used Monte Carlo sensitivity 
analysis and real options analysis as useful decision-
making tools to provide a feel for how investment 
results might be affected by changes to the values of 
critical variables.  
Kenya Case Study Results 
Price to Patient and Cold Chain Failure Improvement 
In addition to profitability, PharmaComp was also 
concerned with reducing price to patient and cold 
chain failure. When comparing the effect of the three 
scenarios on these two factors, it was clear that the 
further the vertical integration, the greater the 
improvement in these two areas. In the As-Is scenario, 
based on mark-up information, the patient pays 217% 
of the original price that PharmaComp sells to 
distributors. In Scenario I, that number falls to 166%, 
and in Scenario II, the price to patient is the lowest at 
136%.  
 
Cold chain failure also improves with vertical 
integration, it is estimated that the As-Is Scenario sees 
failure in up to 20% of products, while Scenario I could 
lower this percentage to as little as 8%, and Scenario 
II could lower the percentage to as little as 2%.. 
 
However, despite the benefits, Scenarios I and II also 
come with risks 
NPV Comparisons 
Another important result of the thesis is the 
comparison of the profitability of Scenario I and 
Scenario II based on changes in the expected demand 
and changes in the additional investment cost that 
would be required to implement Scenario II. In 
general, Scenario II is the better option for instances 
when demand is high and investment cost is low, and 
Scenario I is better for options when the realized 
demand is lower than expected and the investment 
cost required for Scenario II is higher.  
 
Scenario I Sensitivity Analysis 
Scenario I seemed like the method of operation that 
PharmaComp would most likely choose for Kenya, so 
this thesis evaluated the decision to implement 
Scenario I using Monte Carlo sensitivity analysis. The 
analysis took into account fluctuations in demand, 
currency devaluation, and operational costs. The 
findings were that even in cases of low realized 
demand, high currency devaluation, and increased 
operational costs, Scenario I still proved to be more 
profitable than the As-Is Scenario.  
 
Furthermore, when examining contribution of each 
factor to the variance in the NPV (Net Present Value), 
the demand fluctuation was found to account for 
62.2% of the variance. This means that out of all the 
uncertainty that was taken into account in this model, 
demand and market growth rate account for over half. 
Currency devaluation fluctuations were also shown to 
be an important part of PharmaComp’s decision 
process because changes there can account for about 
one third of all the variation in the Scenario I trade off. 
However, changes in operational costs were found to 
be not so important. Rates could increase by up to 
20% and these changes would account for less than 
1% of the uncertainty.  
 
Real Options Analysis 
The final analysis performed in the Kenya Case Study 
is a real option analysis to determine the value of 
waiting until 2020 to make a decision to implement 
Scenario II. It considers that PharmaComp can either 
choose to implement Scenario II right away, or they 
can choose to implement Scenario I today and wait 
until there is more information about the market 
conditions to decide whether or not to implement 
Scenario II.  
 
This analysis found that 68% of the time it was 
beneficial to wait until 2020.  
  
The instances when implementing Scenario II straight 
away was deemed the better option was in 
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circumstances of high demand and/or low investment 
cost. By waiting until 2020 to make a decision about 
Scenario II, PharmaComp is able to maintain some 
flexibility in their strategy. 
Conclusions 
Sub-Saharan Africa is a very fragmented region that 
faces challenges of poor infrastructure, inefficient 
trade, and political and economic instability. The 
decision of which country to select as a foothold in the 
region is an important one for PharmaComp to 
consider, and after building the Scorecard to compare 
the qualitative factors of the Wave I countries, we can 
conclude that Kenya is the country that shows the 
most promise as an option for the company to expand 
their business presence in the SSA region. 
Concurrently, we are also able to conclude that 
PharmaComp supply chain performance can be 
improved by increasing visibility and control over their 
downstream supply chain. Feedback from the 
Benchmark questionnaire indicates that many of the 
downstream problems are linked with lack of 
communication, cold chain failure, counterfeit drugs, 
and backlogs and stockouts. All of these problems 
could be improved upon if there were more supply 
chain visibility.   
Our scenario analysis, which compared Scenario I 
and II as potential options for improving supply chain 
visibility, emphasized the importance of the effect of 
uncertainty in the decision. From our sensitivity 
analysis of Scenario I, we can conclude that even in 
the worst case of lower than expected realized 
demand and higher than expected currency 
devaluation, Scenario I is more profitable than the 
current state of operation. Nevertheless, Scenario II 
shows potential for even further benefit (both from a 
profit perspective and a price to patient perspective). 
However, through our performance of real options 
analysis, we can say that there is more benefit in 
waiting until 2020 than to implement Scenario II today.  
Four years from now, PharmaComp will have more 
information about the potential market and will be able 
to decide if it would be better to stay with the Scenario 
I option or move to using Scenario II. 
Recommendations for Further Study 
Regional cross-border trade is on the rise in Africa. 
African leaders have agreed to create the continent’s 
largest free trade zone known as The Tripartite Free 
Trade Area (TFTA). TFTA covers 26 African nations 
in Eastern and Southern Africa. Thus, a regional 
supply chain network is becoming more and more 
viable. Further research could be conducted by 
PharmaComp to consider ways to segment the market 
that could take advantage of a hub scenario. 
Considering investment, risk, and economic scale, a 
single-hub scenario could be an option for their 
regional network design. A real options analysis 
similar to the one performed in this thesis could be 
performed on a hub scenario to determine if it could 
be beneficial to move to convert Kenya into a hub or 
to wait until a later point in time to make that decision. 
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